Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.

5 China continues to use asbestos and is the top consumer in the world, with an increasing trend of MPM during 2000–2013 and 1659 MPM cases in 2013, but its incidence is low compared with industrialized countries. 5 Newly diagnosed patients with unresectable disease have a median overall survival (OS) of ∼12 months when treated with the standard of care, cisplatin plus pemetrexed. 6 The combination of cisplatin plus pemetrexed is the only currently approved regimen for unresectable first‐line MPM, with approvals gained in 2004 in the USA and European Union, and in 2007 in Japan.

also in 63,971 other papers